(+)-α-Dihydrotetrabenazine-13C2D6

(+)-α-Dihydrotetrabenazine-13C2D6 is a stable, isotopically labeled form of (+)-α-Dihydrotetrabenazine, which is an inhibitor of vesicular monoamine transporter type 2 (VMAT2). VMAT2 is a protein that plays a crucial role in the storage and release of monoamine neurotransmitters such as dopamine, norepinephrine, and serotonin in the brain. By inhibiting VMAT2, (+)-α-Dihydrotetrabenazine-13C2D6 reduces the uptake of monoamines into vesicles and consequently reduces the amount of monoamines released into the synaptic cleft, leading to a decrease in monoaminergic neurotransmission. (+)-α-Dihydrotetrabenazine-13C2D6 is primarily used as a research tool in studies investigating the mechanism of action of VMAT2 inhibitors and their potential therapeutic applications. It can also be used in tracer studies to investigate the pharmacokinetics and metabolism of VMAT2 inhibitors in vivo. The isotopic labeling of (+)-α-Dihydrotetrabenazine-13C2D6 allows for the detection and quantification of the drug and its metabolites using mass spectrometry and other analytical techniques. In summary, (+)-α-Dihydrotetrabenazine-13C2D6 is a valuable research tool for investigating the mechanism of action and pharmacokinetics of VMAT2 inhibitors, which have potential therapeutic applications in conditions such as Parkinson's disease, depression, and schizophrenia.